<DOC>
	<DOCNO>NCT01522469</DOCNO>
	<brief_summary>This Phase II open label study crenolanib besylate . This study enroll subject relapse refractory AML FLT3 activate mutation . Prior treatment FLT3 TKIs allow . Subjects take crenolanib 200mg/m2/day divide three dos daily ( preferably every eight hour ) , take orally least 30 minute pre post meal disease progression , death , patient discontinues treatment adverse event , investigator 's judgment , reason . Patients able proceed allogeneic stem cell transplant able resume crenolanib therapy post-transplant attempt maintain remission .</brief_summary>
	<brief_title>Phase II Study Crenolanib Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<criteria>Relapsed/refractory primary AML AML secondary antecedent hematologic disorder expect survival 3 month great Patients must test positive FLT3ITD /or FLT3 activate mutation within &lt; 60 day screen period . Age ≥18 year ECOG PS 0 2 Adequate liver function , define total direct bilirubin ≤1.5x ULN , ALT ≤3.0x ULN , AST ≤3.0x ULN . Exceptions ALT AST restriction make set document liver involvement leukemia Adequate renal function , define serum creatinine ≤1.5x ULN Recovery nonhematological toxicity prior therapy ( include HSCT ) grade 1 ( except alopecia ) Subjects receive antileukemic therapy ( except hydroxyurea ) prior first dose crenolanib follow : 14 day classical cytotoxic agent five time t1/2 ( halflife ) FLT3 inhibitor antineoplastic agent neither cytotoxic FLT3 inhibitor ( e.g . hypomethylating agent MEK inhibitor ) Negative pregnancy test woman childbearing potential Able willing provide write informed consent Subjects receive crenolanib prior within 3090 day allogeneic stem cell transplant ( HSCT ) either active GVHD therapy initiate GVHD therapy escalate within 14 day prior start study drug Absence FLT3 activate mutation &lt; 5 % blast blood marrow screen Concurrent chemotherapy , systemic immunosuppressant , target anticancer agent , hydroxyurea Patient concurrent severe and/or uncontrolled medical condition opinion investigator may impair participation study evaluation safety and/or efficacy HIV infection active hepatitis B manifest hepatitis surface antigen positive ( HepBsAg ) hepatitis C manifest hepatitis C antibody positive For post HSCT , subject within 29 day allogeneic transplant , and/or unstable dose immunosuppressive drug management prophylaxis GVHD escalate therapy GVHD within 14 day start study drug and/or &gt; /=Grade 2 persistent non hematological toxicity relate transplant receive crenolanib prior HSCT Evidence lack engraftment post allogeneic transplant Unable swallow pill Major surgical procedure within 14 day Cycle 1 Day 1 administration crenolanib Unwillingness inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>FLT3</keyword>
	<keyword>Crenolanib</keyword>
	<keyword>Acute</keyword>
	<keyword>myeloid</keyword>
	<keyword>leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>